Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin’s Lymphoma

2002649 citationsJournal Article

Authors

Ibritumomab tiuxetan radioimmunotherapy is effective in rituximab-refractory patients. The only significant toxicity is hematologic.

Good health and well-being

Published in: Journal of Clinical Oncology

Volume 20, Issue 15, pp. 3262-3269

Field-Weighted Citation Impact: 23.71